Home/Filings/4/0001209191-23-048785
4//SEC Filing

FRIEDMAN CATHY 4

Accession 0001209191-23-048785

CIK 0001806952other

Filed

Sep 7, 8:00 PM ET

Accepted

Sep 8, 4:26 PM ET

Size

8.7 KB

Accession

0001209191-23-048785

Insider Transaction Report

Form 4
Period: 2023-09-08
Transactions
  • Award

    Option (right to buy)

    2023-09-08+55,00055,000 total
    Exercise: $3.19Exp: 2033-09-07Common Stock (55,000 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    236,370
  • Common Stock

    (indirect: By Trust)
    100,000
Footnotes (4)
  • [F1]Received in a pro-rata distribution from Lyell Investors, LLC. The Reporting Person is a trustee of MSL FBO J DUANE & C FRIEDMAN TTEE DUANE FAMILY TRUST ("Duane Family Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Family Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Family Trust except to any pecuniary interest therein.
  • [F2]The Reporting Person is a trustee of The Duane Irrevocable Trust 2020 ("Duane Irrevocable Trust") and therefore may be deemed to share the power to direct the disposition and vote of the shares held by the Duane Irrevocable Trust. The Reporting Person disclaims beneficial ownership of all shares held by Duane Irrevocable Trust except to any pecuniary interest therein.
  • [F3]On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy.
  • [F4]The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date

Issuer

Lyell Immunopharma, Inc.

CIK 0001806952

Entity typeother

Related Parties

1
  • filerCIK 0001411874

Filing Metadata

Form type
4
Filed
Sep 7, 8:00 PM ET
Accepted
Sep 8, 4:26 PM ET
Size
8.7 KB